Mergers & Acquisitions


Current filters:


Popular Filters

826 to 850 of 921 results

EU Commission OKs J&J's buy of Synthes, but with conditions


The European Commission last week cleared under the EU Merger Regulation the proposed $21.3 billion acquisition…

Johnson & JohnsonMergers & AcquisitionsPharmaceuticalSynthes

Human Genome rejects unsolicited takeover bid from GlaxoSmithKline


US drugmaker Human Genome Sciences (Nasdaq: HGSI) revealed yesterday that it has rejected an unsolicited…

BiotechnologyGlaxoSmithKlineHuman Genome SciencesMergers & AcquisitionsPharmaceutical

Roche will not extend its tender offer for Illumina


In view of the apparent re-election of the incumbent directors of Illumina (Nasdaq: ILMN), a leading…

BiotechnologyIlluminaMergers & AcquisitionsPharmaceuticalRoche

Piramal buys molecular imaging portfolio from Bayer


Indian drugmaker Piramal Healthcare (BSE: 500302) says it has signed an agreement to acquire worldwide…

BayerflorbetabenMergers & AcquisitionsPharmaceuticalPiramal Healthcare

Roche ratchets up the pressure on Illumina; analytical view


If there is an axiom to describe Swiss drug major Roche (ROG: SIX), it is that what Roche wants, it gets,…

IlluminaMergers & AcquisitionsPharmaceuticalRoche

Shire inks deal to buy Pervasis, adding Ph II drug candidate


Ireland-headquartered biopharma firm Shire (LSE: SHP) said yesterday that it has signed an agreement…

Mergers & AcquisitionsPervasis TherapeuticsPharmaceuticalShire

Valeant Pharma to acquire podiatry firm Pedinol


In a fourth takeover deal so far this year, Canadian drugmaker Valeant Pharmaceuticals International.…

Mergers & AcquisitionsPedinol PharmacalPharmaceuticalValeant Pharmaceuticals

Takeda to acquire URL Pharma for $800 million


Japanese drug major Takeda Pharmaceutical (TYO: 4502) said yesterday that it has reached agreement to…

ColcrysMergers & AcquisitionsPharmaceuticalTakeda PharmaceuticalsUloricURL Pharma

Arrowhead takes over Alvos Thera in stock deal


USA-based nano-medicine developer Arrowhead Research Corp (Nasdaq: ARWR) says it has acquired Alvos Therapeutics…

Alvos TherapeuticsArrowhead ResearchBiotechnologyMergers & AcquisitionsPharmaceutical

Amgen to snap up KAI Pharma for $315 million


In a second acquisition announced so far this year, global biotech leader Amgen (Nasdaq: AMGN) said yesterday…

AmgenBiotechnologyKAI PharmaceuticalsMergers & AcquisitionsNephrology and Hepatology

Newron licenses safinamide to Zambon for EU and USA


Italian drug developer Newron Pharmaceuticals (SIX: NWRN) says that it has signed a strategic collaboration…

LicensingMergers & AcquisitionsNeurologicalNewron PharmaPharmaceuticalsafinamideZambon

IBA to set up new radiopharma company with SK Capital


Belgium-based Ion Beam Applications (IBA.) and SK Capital Partners, a US private investment firm, have…

IBA MolecularMergers & AcquisitionsPharmaceutical

Investor Icahn slams Amylin for not revealing B-MS bid


Billionaire US investor Carl Icahn has sent a blistering open letter to the board of US biotech company…

AmylinBiotechnologyBristol-Myers SquibbMergers & AcquisitionsPharmaceutical

Roche presses on with takeover, despite further rejection by Illumina board


Swiss drug major Roche (ROG: SIX), admitting disappointment that the board of Illumina (Nasdaq: ILMN)…

IlluminaMergers & AcquisitionsPharmaceuticalRoche

GlaxoSmithKline ups stake in COPD drug partner Theravance


UK pharma giant GlaxoSmithKline (LSE: GSK) has increased its equity stake in USA-based Theravance (Nasdaq:…

GlaxoSmithKlineMergers & AcquisitionsPharmaceuticalTheravance

Government, academic and venture firms come together in March to fund translational and early-stage development


A host of new initiatives focused on funding translational research and early-stage companies brought…

BiotechnologyFinancialMergers & AcquisitionsPharmaceutical

Valeant to buy Russian OTC drugmaker


In its third takeover announcement this year, Canadian drugmaker Valeant Pharmaceuticals International…

Mergers & AcquisitionsNatur ProduktPharmaceuticalValeant Pharmaceuticals

Islet Sciences closes stock acquisition of diabetes drug developer DiaKine


New York. USA-based biotech company Islet Sciences (OTC.BB: ISLT),said Friday that it has closed its…

BiotechnologyDiabetesDiaKine TherapeuticsIslet SciencesMergers & Acquisitions

826 to 850 of 921 results

Back to top